Hansa Biopharma secures $121m for kidney drug

By Sam Kerr
09 Jul 2020

Hansa Biopharma, the Swedish pharmaceuticals company, raised Skr1.1bn ($121m) through a sale of new shares on Wednesday evening to fund the launch of a new drug for patients undergoing kidney transplants.

Morgan Stanley, Kempen & Co were the joint bookrunners on the deal, Zonda Partners was a co-lead manager.

The company 4.4m shares at Skr250 a share, an 8.5% discount to the close the night before.

“It was a pretty good outcome and we had a very good ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial